Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01676116 · ClinicalTrials.gov registry record · Phase 3
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 438
- Enrollment target
NCT01676116 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 438 participants.
The verdict
NCT01676116, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 438 participants
- Enrollment target
Study Summary
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on glucagon-like peptide-1 (GLP-1) receptor agonist and OAD therapy.
Interventions
- DRUG liraglutide
- DRUG exenatide
- DRUG insulin degludec/liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2012-08-29 |
| Est. Completion | 2014-03-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01676116
The ClinicalTrials.gov registry entry for NCT01676116 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 438 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which liraglutide is the first listed.
NCT01676116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01676116 about?
NCT01676116 is a clinical study titled "The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy". This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on glucagon-like peptide-1 (GLP-1) receptor agonist ...
What is the current status of trial NCT01676116?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 438 participants. The study started on 2012-08-29. Estimated completion is 2014-03-11.
What interventions are being tested in trial NCT01676116?
The interventions under investigation include: liraglutide (DRUG), exenatide (DRUG), insulin degludec/liraglutide (DRUG).
Who is sponsoring clinical trial NCT01676116?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.